StratDeck

Two stocks in Healthcare

argenx vs Novo Nordisk A/S: profit, growth, debt and price compared

argenx is stronger on 4 of 6 figures: sales growth, debt, analysts' view and price trend. Novo Nordisk A/S is stronger on 2: profit margin and price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore argenx's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

argenx and Novo Nordisk A/S side by side
argenxARGX.BRNovo Nordisk A/SNOVO-B.CO
Net margin31.7%Stronger: 33.9%
Revenue growth, past yearStronger: +52.10%+5.60%
Debt to equityStronger: 0.6%61.7%
Forward P/E26.9×Stronger: 12.0×
Dividend yield—4.25%
AnalystsStronger: Buy · 23Hold · 24
From its 200-day averageStronger: +11.9%−7.0%

Share price over the past year

  • argenx+9.4%
  • Novo Nordisk A/S−5.4%

24 Nov 202518 Nov 2026

argenx or Novo Nordisk A/S: which is stronger?

  • NOVO-B.CO

    Which is more profitable?

    Novo Nordisk A/S keeps more of each sale as profit: 33.9% against 31.7%.

  • ARGX.BR

    Which is growing its sales faster?

    argenx is growing its sales faster: +52.10% over the past year, against +5.60%.

  • ARGX.BR

    Which has borrowed less?

    argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 61.7% for Novo Nordisk A/S.

  • NOVO-B.CO

    Which costs less for the profit it is expected to make?

    Novo Nordisk A/S costs less for the profit it is expected to make: 12.0× its forward earnings, against 26.9×.

  • Which pays more in dividends?

    Novo Nordisk A/S pays 4.25% a year in dividends for what a share costs, where argenx pays none.

  • ARGX.BR

    Which do analysts rate higher?

    Analysts are warmer on argenx: Buy, against Hold for Novo Nordisk A/S.

  • ARGX.BR

    Which is in the stronger price trend?

    argenx's price is in the stronger trend: 11.9% above its 200-day average, against 7.0% below.

What each company does

ARGX.BRargenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Reports results on 25 February 2027

NOVO-B.CONovo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.